Merck: positive results for HPV vaccine

(CercleFinance.com) - On Wednesday, Merck reported positive results from the Phase III clinical trial of its human papillomavirus (HPV) vaccine candidate in young men.


The study met all primary and secondary endpoints, reducing anogenital infections in Japanese men aged 16 to 26 with three doses of Gardasil 9 versus placebo.

Following these data, Merck explains that it plans to approach health authorities in Japan and other countries to obtain approval for its vaccine in the male population.

Also in men, Gardasil 9 is the subject of another Phase 3 trial designed to assess its efficacy in preventing HPV-related oropharyngeal disease likely to oral persistent infection to support likely to lead to certain cancers.

Copyright (c) 2024 CercleFinance.com. All rights reserved.